EU e-Privacy Directive

This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.

View e-Privacy Directive Documents

You have declined cookies. This decision can be reversed.

Dangerous Diabetes Drug- Consumer Protection

Ronald Grisanti D.C., D.A.B.C.O., D.A.C.B.N., M.S.

What do you do when one of the more recent diabetes drugs has the common "black box" warning?


The drug I am referring too is Avandia® (or generic rosiglitazone).


What does it tell you when the most prestigious and high profile medical journal, New England Journal of Medicine, clearly states that the diabetes drug Avandia increases the heart attack rate a devastating 43%.


What does it tell you when you see plastered all over television attorneys placing huge ads for those injured by the drug?


What is even more worrisome is even though there are over 700 lawsuits from people injured by Avandia, totaling more than $60 million, and even though the human study trials on it had to be ended because it was so dangerous, the FDA was still deciding its fate as of spring 2011.


Would it be pushing the envelope to say that profits may in fact over-rule the protection of the public?


Does that have anything to do with the fact that it brings in over $3 billion in a year.



In fact studies have shown that not only did Avandia triple the death rate over placebo but it increased congestive heart failure and raised the bad cholesterol, LDL, 18%.


Just how many millions of dollars, thousands of harmed people and hundreds of doctors does it take to prove that diabetes is not a deficiency of the latest drug?


For many of you reading this short consumer protection update, I simply make it a point to report things as they are.


The goal is to help each and every one of my readers to become better health care consumers and to be extremely knowledgeable on seeking to identify what in fact may be at the root of their health issues.


You really need to have a heart to heart talk with yourself and ask if you simply want to settle with the one size fits all drug approach or would you rather seek the expertise of a physician who seeks to find the underlying root cause of a disease.


That is the power of functional medicine and that power comes from doing a thorough clinical investigation in what are the issues that have led to the disease in the first place.



Nissen SE, et al, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in New Engl J Med, 2007; 357 (1): 100] New Engl J Med 356; 24:2457-71, 2007


Mitka M, Critics press FDA to act on evidence of rosiglitazone's cardiac safety issues, J Am Med Assoc, 303;23:2341-2, 2010


Nissen SE, Setting the RECORD straight, J Am Med Assoc, 303; 12:1194-1195, 2010




The information on this website is not intended to replace a one-on-one relationship with a qualified health care professional and is not intended as medical advice. It is intended as a sharing of knowledge and information from the research and experience of Dr. Grisanti and his community. Dr. Grisanti encourages you to make your own health care decisions based upon your research and in partnership with a qualified health care professional. Visit www.FunctionalMedicineUniversity.com to find practitioners thoroughly trained in functional medicine. Look for practitioners who have successfully completed the Functional Medicine University's Certification Program (CFMP).


This content may be copied in full, with copyright, contact, creation and information intact, without specific permission, when used only in a not-for-profit format. If any other use is desired, permission in writing from Dr. Grisanti is required.


REGISTERED: Handelsregister Schwyz
COMPANY NUMBER: CH-1029-379-06
TAX NUMBER: 1029-379-06
Copyright © 2017. All Rights Reserved.
Institute for Biomodulation Medicine AG

PHONE: +41 41 5003753 FAX: +41 41 5003754



This week3779
This month10643

Thursday, 12 December 2019 23:30